Radiation plus Chemo-Immunotherapy shows promise in breast cancer trial
NCT ID NCT07254858
First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 26 times
Summary
This study tests whether adding a precise, high-dose form of radiation (SBRT) to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with a common type of breast cancer (HR+/HER2-). The trial will enroll 302 adults with high-risk features, such as larger tumors or positive lymph nodes. Participants will be randomly assigned to receive either chemo-immunotherapy alone or with the added radiation, and researchers will compare how well the tumors shrink or disappear before surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.